medigraphic.com
Revista Mexicana de Coloproctología Enfermedades del Ano, Recto y Colon

2006, Number 2

<< Back

Rev Mex Coloproctol 2006; 12 (2)

Sinchronic colonic cancer

Guerra-Melgar DA, Guerra-Melgar LR, Inda-Toledo A

Language: Spanish
References: 16
Page: 90-93
PDF size: 273.21 Kb.


ABSTRACT

We present the case of a 42 years old male, with 8 months of superior abdominal pain, hematoquezia and loss weight. In the colonoscopy we find proliferative growth lesions in ascending and transverse colon, as well as an stenotic lesion in descending colon. The patient underwent a surgical procedure and the anathomopathologics findings report a well differentiated adenocarcinoma in the stenotic lesion with concurrent in situ carcinoma and focal invasion of submucosa layer with mucinous areas in the rest of lesions, defying an sinchronic colonic cancer. The procedure realized was a subtotal colectomy with ileorectal anastomosis, the patient has an adequate recovering free of tumor at this time.


REFERENCES

  1. Pfister DG, Benson B. Surveillance strategies after curative treatment of colorectal cancer. N Engl J Med 2004; 35(23): 2375-2382.

  2. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, 10.ª ed. Lyon: IARC Press, 2001.

  3. Fenneth SA, Mark F, Uric L. Fecal DNA testing compared with conventional colorectal cancer screening methods: A decision analysis. Gastroenterology 2004; 126: 1270-1279.

  4. Winawer SJ, Fletcher RH, Miller L, Godlee F, Stolar MH, Mulrow CD et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997; 112: 594-642.

  5. Giovannucci E. Modifiable risk factors for colon cancer. Gastroenterol Clin North Am 2002; 31: 925-943.

  6. Riboli E, Norat T. Epidemiologic evidence of the protective effect of fruit and vegetables on cancer risk. Am J Clin Nutr 2003; 78: 559S-569S. [Medline].

  7. Bingham SA, Day NE, Luben R, Ferrari P, Slimani N, Norat T et al. Dietary fiber in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. Lancet 2003; 361: 1.496-1.501. [Medline].

  8. Ransohoff DF, Sandler RS. Screening for colorectal cancer. N Engl J Med 2002; 346(1): 40-44.

  9. Mayer RJ. Two steps forward in the treatment of colorectal cancer. MD N Engl J Med 2004; 35(23): 2406-2407.

  10. Crosland A, Jones R. Rectal bleeding: prevalence and consultation behaviour. BMJ 1995; 311: 486-488.

  11. Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000; 343: 1.603-1.607.

  12. Thierry A, Corrado B. Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350(23): 2343-2351.

  13. Sharan R, Schoen RE. Cancer in inflammatory bowel disease. An evidence-based analysis and guide for physicians and patients. Gastroenterol Clin North Am 2002; 31: 237-254.

  14. Lavery IC, Lopez-Kostner F, Pelley RJ, Fine RM. Tratamiento del cáncer de colon y recto. Clin Quir Norteam (ed. esp.) 2000; 2: 537-74.

  15. Hardy TG. Cancer of the colon. In: Fazio VW, editor. Current therapy in colon and rectal surgery. Burlington, Ontario: BC Decker Inc. 1990: 301-10.

  16. Nelson H, Petrelli N, Carlin A, Couture J, Fleshman J. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 2001; 93: 583-96.




2020     |     www.medigraphic.com